US Patent Litigations are now available. Check here

Explore Ganymed Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 10, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3126381Feb 16, 2022Claudin-6-Specific Immunoreceptors And T Cell Epitopes2
EP3254695Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2